Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.72 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | NT5E | P21589 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | TOP2A | P11388 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13293148 | 0.92 | SLC10A1 (0.71) | SLC10A1GPBAR1LMNANT5ESMN1; SMN2 | |
| SCHEMBL23626105 | 0.92 | GPBAR1 (0.70) | SLC10A1GPBAR1LMNANT5ESMN1; SMN2 | |
| SCHEMBL13098061 | 0.92 | GPBAR1 (0.70) | SLC10A1GPBAR1LMNANT5ESMN1; SMN2 | |
| SCHEMBL13910810 | 0.92 | GPBAR1 (0.70) | SLC10A1GPBAR1LMNANT5ESMN1; SMN2 | |
| SCHEMBL13304150 | 0.92 | SLC10A1 (0.70) | SLC10A1GPBAR1LMNANT5ESMN1; SMN2 | |
| SCHEMBL13910811 | 0.90 | GPBAR1 (0.62) | SLC10A1GPBAR1LMNANT5ESMN1; SMN2 | |
| SCHEMBL13910812 | 0.89 | GPBAR1 (0.61) | SLC10A1GPBAR1LMNANT5ESMN1; SMN2 | |
| SCHEMBL13910804 | 0.89 | LMNA (0.61) | SLC10A1GPBAR1LMNANT5ESMN1; SMN2 | |
| SCHEMBL13910784 | 0.88 | GPBAR1 (0.59) | SLC10A1GPBAR1LMNANT5ESMN1; SMN2 | |
| SCHEMBL13301993 | 0.87 | SLC10A1 (0.70) | SLC10A1GPBAR1LMNANT5ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062243-A1 | Lupane-Type Triterpenoids Modified at 30-Position and Analogues Thereof | ADVANCED LIFE SCIENCES, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| WO-2009020732-A1 | LUPANE-TYPE TRITERPENOIDS MODIFIED AT 30-POSITION AND ANALOGUES THEREOF | ADVANCED LIFE SCIENCES, INC. (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062243-A1 | Lupane-Type Triterpenoids Modified at 30-Position and Analogues Thereof | BRCA1, PGF, GPER1 | SLC10A1 873/4885GPBAR1 276/4885LMNA 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.